Science

Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.

Dipesh Uprety and Jacob Sands

Jan 12, 2025, 13:43

Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.

Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X about recent paper by Jacob Sands, Medical oncologist at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“TROPION-Lung05: a phase II trial.

Patients with advanced/metastatic NSCLC with actionable genomic alterations after disease progression on targeted therapy and chemotherapy received Dato-DXd.

ORR 35.8%, DCR 78.8%, Median DoR 7 months.”

“Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study”

Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares, et al.

Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.

More posts featuring Dipesh Uprety.

Aaron Lisberg cancer datopotamab deruxtecan Dipesh Uprety Jacob Sands Luis Paz-Ares Myung-Ju Ahn non-small cell lung carcinoma NSCLC OncoDaily Oncology Rachel Chiaverelli TROPION-Lung05 Study

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial